T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.
Ontology highlight
ABSTRACT: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy characterized by aberrant proliferation of immature thymocytes. Despite an overall survival of 80% in the pediatric setting, 20% of patients with T-ALL ultimately die from relapsed or refractory disease. Therefore, there is an urgent need for novel therapies. Molecular genetic analyses and sequencing studies have led to the identification of recurrent T-ALL genetic drivers. This review summarizes the main genetic drivers and targetable lesions of T-ALL and gives a comprehensive overview of the novel treatments for patients with T-ALL that are currently under clinical investigation or that are emerging from preclinical research.Significance
T-ALL is driven by oncogenic transcription factors that act
SUBMITTER: Cordo' V
PROVIDER: S-EPMC8447273 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA